Randomized Controlled Trial of a Psychosocial Mobile Application (App) to Promote Coping for Patients With Chronic Graft-Versus-Host Disease (GVHD)
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD)
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adult patients (≥18 years) who underwent allogeneic hematopoietic stem cell transplant (HCT).
• Have moderate to severe chronic GVHD based on their oncology clinician assessment as documented in the Electronic Health Record.
• Ability to comprehend and speak English as the HORIZONs app is only available in English.
Locations
United States
Massachusetts
Massachusetts General Hospital Cancer Center
RECRUITING
Boston
Contact Information
Primary
Areej El-Jawahri, MD
AEL-JAWAHRI@PARTNERS.ORG
617-643-4003
Time Frame
Start Date: 2023-01-23
Estimated Completion Date: 2025-04-01
Participants
Target number of participants: 120
Treatments
Experimental: Horizons mobile app
Participants randomly assigned to the Horizons group, will use the Horizons app over an eight-week period in addition to receiving usual care from transplant team.~Participants will complete study questionnaires at the time of enrollment (baseline) and at eight and sixteen weeks after enrollment
Active_comparator: Usual Care
Participant in the usual care group will receive usual care from the transplant oncology team including all the supportive care measures implemented by the transplant oncology team.~Participants will complete study questionnaires at the time of enrollment (baseline) nad at eight and sixteen weeks after enrollment
Related Therapeutic Areas
Sponsors
Leads: Massachusetts General Hospital
Collaborators: The Leukemia and Lymphoma Society